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Abstract 
Synthesis and characterization by spectroscopic, X-ray and hypoglycemic activity study of 
copper complex with gliclazide (N-(hexahydrocyclopenta[c]-pyrrol-2(1H)-ylcarbamoyl)-4-
methylbenzenesulfonamide) an oral antidiabetic drugs. The conductometric titration using 
monovariation method indicate that complex are non-ionic and L2M (2:1) type. Analytical 
data agree with the molecular formula (C15H20N3O3S)2Cu. of complex for gliclazide. The 
structure of complex was assigned square planner supported by IR, 1H-NMR, X-Ray, mass 
studies and propose structure (I) for complex.Alloxan induced model have been used to 
compare hypoglycemic activity of gliclazide complex. 
Keywords: Gliclazide, Oral antidiabetic drugs, Complexes, IR, NMR. X-Ray, Hypoglycemic 
activity. 
 
 1. Introduction 
      Metal ion are required for many critical function in humans .Scarcity of some metal ions 
can leads to disease1. Well – known  example  can  leads  to  pernicious anemia   resulting 
from  iron  deficiency;  growth  retardation  arising from  insufficient  dietary  zinc, and  heart  
disease in  infants  owing  to copper  deficiency. The ability to  recognize, to understand  at 
the  molecular  level and to the diseases  caused  by  inadequate  metal- ion function  
constitutes  an important  aspect  of  medicinal  bioinorganic chemistry.  Understanding   the  
biochemistry  and  molecular biology of  natural  detoxification  mechanisms  and  designing  
and  applying  ion–specific  chelating agents  to  treat  metal  over-loads  are  the  two  
components  of   a  second  major  aspect  of  the  new  science  that  is  evolving  at  the  
interface  of   bioinorganic  chemistry  and  medicine. 
Diabetes   is  a  deceptive  disease  and  if  not  detected  in  early  stage  may  cause  even  
death.  It  is  considered  hereditary  but  actual  genetic  disorder  is  still  a  mystery.  Several  
million  people  are  suffering from  this disease all over  the  world (Sadilot  and Phatak2, 
Bloomgarden3, Sanger  and  Thompson,4 ). Zinc- insulin was discovered as early as in 1921 
and later it proved to be a very  efficacious  medicine in the treatment  of  diabetes mellitus. 
To  avoid  the daily pricks  of hypodermic syringe, oral hypoglycemic agents were discovered 
which has revolutionized the treatment of  diabetes .It is worthwhile to mention here that the 
majority of the essential metallic elements   of biological importance  are transition metals, 
whose ability to form coordination complexes and chelates is the characteristic aspects of 
their chemistry. 
In  recent  years  much  attention is given to the use of  sulphonyl-ureas  because of their high 
complexing  nature with essential  metals. Sulphonyl-ureas  are effective  for non- insulin 
dependent  diabetes mellitus, (Sadilot and Phatak2,  Bloomgarden,3  Sanger and Thompson,4). 
These compounds are completely absorbed  on oral  administration. They are metabolized by 
liver and are excreted predominantly through urine. 
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Complexation  of sulphonyl-ureas with lighter transition metals has been  studied in detail  by  
Yoshinaga and Yamamotto5-6, Iqbal at.el., 7, 10, 11. A perusal of available literature shows that 
systematic study of complexation of copper with gliclazide is relatively scanty. It is 
interesting to have an insite in to the synthesis of copper complex with gliclazide and to 
diagnose various structural aspects of the isolated complex. 
Here the synthesis and characterization of copper with gliclazide have been described 
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2. Experiment  
2. 1.Ligand-Metal Ratio 
a) Pure gliclazide m.p. 180°C (Lit. 179.5-180.5), 0.005 M, pure were diluted to 100ml.  
and titrated conductometrically against cupric chloride at 30±1°C. results were 
plotted in the form of graph which indicate ligand metal ratio as 2:1 (L2M). 
b) Formation of 2:1 (L2M) ratio was further confirmed by Job’s method8 of continuous 
variation as modified by Turner and Anderson9(Table-1) spectrophotometric studies 
were conducted using absorbance as index property, from these values the stability 
constant (log k) and free energy change    (-∆F), were also calculated Tables 1, and 
fig. 1 given for gliclazide -copper complex. 
                                                    
 
                           Table-1  GLICLAZIDE WITH CUPRIC CHLORIDE                                                          
Gliclazide-0.002M, 0.005M                      Cupric chloride-0.002M,0.005M              Solvent: 
90% Ethanol                                                Temperature: 310C±1           Wavelength: 610 nm                                                              
pH: 6.4 
S.No. Metal:Ligand ratio            Absorbance Corrected Absorbance 
0.002M 0.005M 0.002M 0.005M 
1 0:12 0.006 0.01 0.00 0.00 
2 1:11 0.065 0.095 0.059 0.085 
3 2:10 0.112 0.135 0.106 0.125 
4 3:9 0.167 0.19 0.161 0.175 
5 4:8 0.205 0.260 0.198 0.241 
6 5:7 0.185 0.240 0.178 0.220 
7 6:6 0.145 0.198 0.138 0.185 
8 7:5 0.098 0.123 0.090 0.109 
9 8:4 0.090 0.112 0.082 0.099 
10 9:3 0.052 0.075 0.044 0.065 
11 10:2 0.033 0.043 0.025 0.029 
12 11:1 0.021 0.025 0.020 0.019 
13 12:0 0.009 0.014 0.00 0.00 
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Fig.1  Job’s Method of continuous variationas modified by Turner and Anderson 
 
2.2 Synthesis of Complex 
The chemicals used in this synthesis were all of AnalaR grade and Hi-media. A weighed 
quantity of Gliclazide (2 mole) (supplied by Zim laboratory, Nagpur) was dissolved 
separately in minimum quantity of 90% ethanol. The cupric chloride solution was prepared by 
dissolving (1 mole) separately in the same solvent. Ligand solution was added slowly with 
stirring into the metallic salt solution at room temperature, maintain the pH between 6.0 to 6.5 
by adding dilute NaOH solution. On refluxing the mixture for 3 hour and on cooling the 
complex separated out. Which was filtered, washed well with ethanol and finally dried in 
vacuum and weighed. 
 
The elemental analysis of the isolated complex was carried out using Coleman Analyzer at the 
Departmental Microanalytical Laboratory CDRI Lucknow. The IR spectra of the ligand as 
well as of the complex was recorded on Perkin Elemer Spectrometer(I.I.T Bombay) and 1H 
NMR spectra of the ligand and isolated complex was recorded on a Bruker DRX-300 
spectrometer and d6-DMSO was used as a solvent.            1H-NMR spectra recorded in CDRI 
Lucknow. India, and X-Ray diffractrogram from Punjab University, Chandigarh, India. From 
stoichoimetry and analytical data, the composition of the complex comes out to be 
(C15H21N3O3S)2Cu,  which favours 2:1 (L2M) ratio. The tentative structure (I) assigned to 
complex on the basis of analytical data and IR, NMR and X-ray studies. 
                                     
3.   Result  
3.1 Table-2 Physico-chemical characterstics of gliclazide-copper complex  
 
S. 
No. 
Complex Color Yield 
(%) 
m.p.°C  
–ΔF   
Log K Molar conductance 
Ω-1cm-1mole-1 
1. (C15H21N3O3S)2 Cu Maple green 58.79 169 16.65 12.022 30.1 
S.No. Formula of complex Molecular 
weight 
(g/mol) 
Analytical data calculated (theoretical) 
C 
 
H 
 
N 
 
S 
 
Metal 
(%) 
1. (C15H21N3O3S)2Cu 708 50.19 
(50.50) 
6.00 
(6.01) 
10.47 
(11.47) 
9.00 
(8.47) 
7.99 
(7.75) 
 
3.2 X-Ray Diffraction Studies. 
                                             X-ray diffraction studies also confirm the complex and formation 
due to new bonds 10-23. The number of peaks in gliclazide are 22 while (GLZ)2Cu are 10 
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(Fig.2) . Thus indicating that complex formed is a well kit one. All the reflections present are 
new ones and the patterns are fairly strong. On comparing the pattern obtained with available 
literature. It is evident that its pattern is not in good agreement with available information and 
thus confirms the formation of totally new complex. The X-ray pattern have been indexed by 
using computer software(FPSUIT 2.0V) and applying interactive trial and error method 
keeping in mind the characteristics of the various symmetry system, till a good fit was 
obtained between the observed and the calculated Sin2θ value. The unit cell parameters were 
calculated from the indexed data and given below, from cell data and crystal lattice 
parameters of (GLZ)2Cu, indicates complex attributed to orthorhombic crystal system Table 
3. a(Å) = 21.762, b(Å) = 23.4271, c(Å) = 27.274, α=90°, β=90, γ =90°, Volume (abc)Å= 
14062.94, Dcal=5.39107g/cm3 , Dobs=5.40791g/cm3   , Crystal system= orthorhombic,              
Porosity(%) = 4.411, Density =0.05473g/cm3, Particle size =   15.0 microns, Space group = 
Pmmm 
 
 
                                              
                                  
 
 
           Fig.2 X-ray diffractrogram of gliclazide-copper complex     
                                               
         Table-3 Cell data and crystal parameter of gliclazide-copper complex 
                                                                              
 
2θ I/I0 D(Obs) D(Cal) h k l 
16.3917 
17.8081 
22.8482 
23.8088 
31.7966 
32.4666 
34.2064 
39.8484 
50.0436 
53.5242 
100 
20.64 
8.89 
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32.84 
62.17 
16.25 
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3.3 Infra-red Spectra Studies 
The IR spectra of ligand and isolated complex (Fig.3) was recorded within the range 4000-
400 cm-1. Assignments (Table-4)  of the infrared spectral bands are based on literature. IR 
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spectrum shows important bands due to ν(M-O) 500-600 cm-1, ν(Ar-S) 700-800 cm-1, ν(-S-N) 
1085±20 cm-1, ν(SO2-N) 1120±20 cm-1, ν(C-N) 1210±20 cm-1, ν(S=O) 1340±20 cm-1, 
ν(C=O) 1710 cm-1, ν(NH-stretch) 3274±20 cm-1. The proposed structure for the isolated 
complex is also supported by IR absorption 23-28.  
 
 
               Fig.3 gliclazide –copper complex 
 
                                                             
Table -4 Specific IR assignment of gliclazide (ligand) and gliclazide complex with Cu(II) 
Pure drug (Gliclazide) Gliclazide-Cu complex 
632 cm
-1
s, 668 cm
-1
 vs, 1087cm
-1
vs 
1240 cm
-1
vs,1348 cm
-1
vs,1710 cm-1vs, 2867cm
-1
, 
2950 cm
-1
vs, 3274cm
-
1vs 
Vs=very strong, s=strong, m=medium 
W=weak 
547cm
-1
 s ,753 cm
-1
 vs,1122 cm
-1
s,        1216 cm
-
1
vs ,1622 cm
-1
vs, 1337cm
-1
 s, 1524cm
-1
s,  2947cm
-
1
m, 3021cm
-1
s,     3674 cm
-1
m, Vs=very strong, 
s=strong, m=medium, W=weak 
 
3.4 1H-NMR Studies  
1H-NMR spectral (Fig.4) data are given in (Table-5). It was observed that the singlet due to 
the imide (NH) proton around (δ8.033) in the spectrum of the ligand disappeared in the 
spectra of (NH) group in the complex molecule due to formation of M-O band. This also 
confirms the deprotonation of imide NH group through enolization (the appearance of >C=N 
stretching band observed in IR spectra). Other features of NMR spectrum were the aromatic 
presence of unresolved multiplet suggestive protons 29-38.  
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  Fig-4 1H NMR spectra of gliclazide-copper complex 
 
Table-5 NMR-Assignments of gliclazide-copper complex 
(C15H21N3O3S)2 pure drug Gliclazide (C15H20N3O3S)2Cu 
δ8.041 (s,1H,NHCO, J=0.334Hz), δ7.817 
(d,benzene J=1Hz), δ7.395 (d,benzene, J=1Hz), 
δ6.28 (s,SO2NH), δ3.320 (NH-CO, J=0.929Hz), 
δ2.901 (s,CH3 group attached to benzene, 
J=2.160 Hz), δ1.388 (s,CH3 group, J=2.955Hz, 
s=singlet, d=doublet, t=triplet, q=quartrate, 
m=multiple               
 
δ7.691 (d,1H,NH-CO, J=1Hz), δ7.346 (d,benzene, 
J=0.69Hz), δ6.328 (s,SO2-NH, J=1Hz), δ3.668 
(s,NH-CO-Cu, J=0.83Hz), δ2.724 (s,CH3-group 
attached to benzene, J=1.26Hz), δ1.608 (q,CH3 
group,J=5.50Hz), δ1.009 (CH3 group,J=2.03HZ 
3.5 Mass Spectral Study 
The mass spectra of Cu(II) complex of the gliclazide, peaks attributable to the related 
molecular ions m/z 713.1[M-2H]2+, m/z 1068[M-2H]2+,324[M-H] 2+      respectively 38-48. The 
observed free ligand Gliclazide peaks for Cu(II),  m/z 324.1 [L+H]+.  The mass spectra of the 
complex is given in Fig. 5 and assignment are m/z 713 due to [Cu(C15H19N3O3S)2]+. or 
(ML2)+. Molecular ion peak (m+.); m/z 366 due to (C18H19N6O3)+. fragment ion. m/z 324 due 
to [C15H21N3O3S]+. Base peak ion 100% relative abundance. 
 
Fig.5 Mass spectra of gliclazide-copper complex 
 
3.6 Hypoglycemic Studies 
Pharmacology is mainly concerned with the responses of living organisms to chemical 
stimuli. One may further divide the subject from a medical view point, into 
pharmacodynamics and pharmacotherapy , the former is concerned with the response of living 
organism to chemical stimuli in the absence of disease, while the later with the response of 
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organism to such stimuli in a pathogenic state. This is the phase of pharmacology (i.e. 
pharmacotherapy) which is of special interest to the physician.  
Pharmacotherapy includes the treatment of the sick with drugs and therefore is of prime 
importance in practice of medicine. It is fundamental to the health-economy of the people. A 
compound or a complex which is to be recommended as a drug of utility must be capable of 
easy absorption and excretion. It is also essential that neither the absence itself nor the 
metabolic products thereof should exercise toxicity or any adverse side effect to the patient. 
1. Animal Study- Where necessary such tests should be carried out on animals as rats, 
rabbits and dogs. When a substance has given satisfactory results for the aforesaid 
animals then only it may be tried on monkeys and men. 
2. In present study we analyze  the hypoglycemic activity on albino rats:- 
 
Animal care and handling 
The anti-diabetic activity was carried out on Wistar albino rats of 4 months of both sexes, 
weighing between 140 to 200 gm. They were provided from Sapience Bio-analytical Research 
Lab, Bhopal, (M.P.). The animals were acclimatized to the standard laboratory conditions in 
cross ventilated animal house at temperature 25±2°C relative humidity        44 –56% and light 
and dark cycles of 12:12 hours,  fed with standard pallet diet and  water ad libitum during 
experiment. The experiment was approved by the institutional ethics committee and as per 
CPCSEA guidelines (approval no. 1413/PO/a/11/CPCSEA). 
Chemicals 
Alloxan monohydrate was purchased from Central Drug House (P) LTD. Gliclazide was 
provided as gift sample by Zim laboratories, Nagpur. All other chemicals used for this study 
were of analytical grade. 
 
Induction of diabetes by alloxan 49, 50 
The diabetes was induced by a single intraperitoenal injection of a freshly prepared solution 
of Alloxan monohydrate (120 mg/kg body weight) Hyperglycemia was confirmed on the third 
day of Alloxan-injection. Rats with moderate diabetes having hyperglycemia (with blood 
glucose above150 mg/dl) were taken for the experiment.  
Experimental Design 
In the experiment, a total of 24 rats were used. The rats were divided into 4 groups, 
comprising of 6 animals in each group as follows: 
Group I: Normal control rats received 1ml/100gm of  0.5% CMC (carboxy methyl cellulose) 
using an intragastric tube for 4 days. 
Group II: Negative control rats received Alloxan 120g/kg, i.p. for inducing diabetes. 
Group III: Rats received gliclazide (2mg/kg body weight per orally) for 4 days and Alloxan 
120g/kg, i.p.  on 1st  day. 
Group IV Rats received gliclazide-copper complex, (2mg/kg, per orally.) once daily for 4 
days and Alloxan 120g/kg, i.p.  on 1st day 
Sample collection 
At the end of study, Blood samples were collected through tail vein and blood glucose levels 
were estimated using an electronic glucometer (Gluco chek) and result is given in table 6 & 7. 
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Table-6 Hypoglycemic activity of gliclazide and its complex with copper at 3
rd 
day (mg/dl) 
Group-I Group-II Group-III Group-IV 
90 108 175 170 
95 157 180 175 
105 160 168 195 
106 122 170 187 
109 170 195 167 
85 165 190 155 
                                                      
                                          
Table-7 Hypoglycemic activity of gliclazide and its complex with copper at 7
rd 
day (mg/dl) 
Group-I Group-II Group-III Group-IV 
107 112 135 115 
89 180 130 120 
97 188 140 125 
110 132 135 98 
102 197 126 120 
98 197 125 112 
 
Discussion 
          For supporting the proposed structure of copper-gliclazide complex, initially Job,s 
method of continuous variation as modified by Turner and Anderson was conducted which 
indicate 2:1 ligand:metal ratio of the complex , moreover  stability constant and free energy 
change was also calculated .Analytical data(Table.2) agrees to the molecular formula 
(C15H20N3O3S)2Cu    (L2M) . 
For determining the proposed structure on the basis of stoichiometry and analysis of the 
complex. Advance spectroscopic methods like IR, 1H NMR, Mass were conducted which 
suggest the coordination of metal atom with enolic oxygen of the carbonyl group on one side 
and oxygen of the sulphonyl group from the other side .These observation were further 
supporting from the IR(Table.4) and NMR(Table.5) values of metal-oxygen and 
disappearance of M-H linkages in NMR. A detailed study of X-Ray (Table-3) also supports 
the complex formation and the various values like particle size, porosity, volume of unit cell, 
density as well as crystal system was evaluated  and discussed. Moreover looking to the 
higher electronegativity of oxygen as compared to N2  and to enolization  is strongly 
supported. Copper complex of gliclazide was evaluated for their hypoglycemic effect on 
experimental rats using alloxan induced diabetes model. The effect of copper complex of 
gliclazide on blood glucose level at 3rd and 7th day in alloxan induced diabetes in rats shown 
in table-6, 7 respectively. So from table we can conclude that copper complex of gliclazide 
have more hypoglycemic activity as compared to parent drug. These interesting observations 
on metal-complex of oral sulphonyl-urea used as anti-diabetic agents for lowering blood sugar 
concentration may likely substantiate the use of these complex after extensive clinical studies. 
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                                         Structure (I) for gliclazide-copper complex                                       
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